The original drug in this class, amphetamine, has been modified by various substitutions on its phenyl ring, resulting in many variations, including methamphetamine, methylenedioxymethamphetamine (Ecstasy, MDMA), methylenedioxyethylamphetamine (MDEA), and numerous others.
Some amphetamines, including dextroamphetamine, methamphetamine, and the related methylphenidate, are widely used medically to treat attention-deficit hyperactivity disorder, obesity, and narcolepsy, thus creating a supply subject to diversion for illicit use. Methamphetamine is easily manufactured illicitly.
Amphetamines enhance release of catecholamines, increasing intrasynaptic levels of norepinephrine, dopamine, and serotonin. The resulting marked alpha- and beta-receptor stimulation and general central nervous system excitation account for the “desired” effects of increased alertness, euphoria, and anorexia, as well as the adverse effects of delirium, hypertension, hyperthermia, and seizures.
Effects of amphetamines are similar, varying in intensity and duration of psychoactive effects; MDMA and its relatives have more mood-enhancing properties, perhaps related to a greater effect on serotonin. Amphetamines can be taken orally as pills or capsules, nasally by inhaling or smoking, or by injection.
Repeated use of amphetamines induces dependence. Tolerance develops slowly, but amounts several 100-fold greater than the amount originally used may eventually be ingested or injected. Tolerance to various effects develops unequally. Tachycardia and increased alertness diminish, but hallucinations and delusions may occur.
Amphetamines typically cause erectile dysfunction in men but enhance sexual desire. Use is associated with unsafe sex practices, and users are at increased risk of sexually transmitted infections, including HIV infection. Amphetamine abusers are prone to injury because the drug produces excitation and grandiosity followed by excess fatigue and sleepiness.
Necrotizing vasculitis that involves multiple organ systems can occur.
Use of certain amphetamine-related appetite suppressants (dexfenfluramine, fenfluramine, phentermine) has been associated with valvular heart disease. Dexfenfluramine and fenfluramine were removed from the US market in 1997. Phentermine-fenfluramine (Phen-fen) products were similarly withdrawn from the US market, but phentermine alone and in combination with topiramate is available as an anorectic.
Many psychologic effects of amphetamines are similar to those of cocaine; they include increased alertness and concentration, euphoria, and feelings of well-being and grandiosity. Palpitations, tremor, diaphoresis, and mydriasis may also occur during intoxication.
Binges (perhaps over several days) lead to an exhaustion syndrome, involving intense fatigue and need for sleep after the stimulation phase.
Tachycardia, arrhythmias, chest pain, hypertension, dizziness, nausea, vomiting, and diarrhea can occur. Central nervous system effects include acute delirium and toxic psychosis. Overdose can also cause stroke (usually hemorrhagic), seizures, muscle rigidity, and hyperthermia (>40° C); all of these effects may precipitate rhabdomyolysis, which can lead to renal failure.
A paranoid psychosis may result from long-term use of amphetamines; rarely, the psychosis is precipitated by a single high dose or by repeated moderate doses. Typical features include delusions of persecution, ideas of reference (notions that everyday occurrences have special meaning or significance personally meant for or directed to the patient), and feelings of omnipotence. Some users experience a prolonged depression, during which suicide is possible.
Recovery from even prolonged amphetamine psychosis is usual but is slow. The more florid symptoms fade within a few days or weeks, but some confusion, memory loss, and delusional ideas commonly persist for months.
Users have a high rate of severe tooth decay affecting multiple teeth; causes include decreased salivation, acidic combustion products, and poor oral hygiene.
Although no stereotypical withdrawal syndrome occurs when amphetamines are stopped, electroencephalogram changes occur, considered by some experts to fulfill the physical criteria for dependence. Abruptly stopping use may uncover or exacerbate underlying depression or precipitate a serious depressive reaction. Withdrawal is often followed by 2 or 3 days of intense fatigue or sleepiness and depression.
Diagnosis of amphetamine use is usually made clinically, although when history of drug use and the diagnosis are unclear, tests are done as indicated for the undifferentiated patient with altered mental status, hyperpyrexia, or seizures. Evaluation then typically includes CT, lumbar puncture, and laboratory tests to identify infections and metabolic abnormalities.
Amphetamines are usually part of routine urine drug screens, which are done unless history of ingestion is clear; specific drug levels are not measured. Immunoassay urine screening tests for amphetamines may produce false-positive results and may not detect methamphetamine and methylphenidate.
When a significant amount of amphetamines has recently been taken orally (eg, < 1 to 2 hours), activated charcoal may be given to limit absorption, although this intervention has not been shown to reduce morbidity or mortality. Urinary acidification hastens amphetamine excretion, but it does not decrease toxicity and may worsen myoglobin precipitation in the renal tubules and thus is not recommended.
Benzodiazepines are the preferred initial treatment for central nervous system excitation, seizures, tachycardia, and hypertension. Lorazepam 2 to 3 mg IV every 5 minutes titrated to effect may be used. High doses or a continuous infusion may be required. Propofol, with mechanical ventilation, may be required for severe agitation. Ketamine 4 mg/kg IM or 2 mg/kg IV may help with severe agitation. Hypertension that does not respond to benzodiazepines is treated with nitrates (occasionally nitroprusside) or other antihypertensives as needed, depending on the severity of the hypertension. Beta-blockers (eg, metoprolol 2 to 5 mg IV) may be used for severe ventricular arrhythmias or tachycardia.
Hyperthermia can be life threatening and should be managed aggressively with sedation plus evaporative cooling, ice packs, and maintenance of intravascular volume and urine flow with IV normal saline solution.
Phenothiazines lower seizure threshold, and their anticholinergic effects can interfere with cooling; thus, they are not preferred for sedation.
No specific treatment is needed when patients stop taking of amphetamines. Blood pressure and mood should be monitored initially. Patients whose depression persists for more than a brief period after amphetamines are stopped may respond to antidepressants.
Cognitive-behavioral therapy (a form of psychotherapy) is effective in some patients. There are no other proven treatments for rehabilitation and maintenance after detoxification.